Lamotrigine-Associated Progressive Dysphasia and Cognitive Dysfunction
Lamotrigine is generally accepted as a well-tolerated medication with few cognitive side effects. Here, we report a case of a 62-year old female with a severe, rapidly progressive dementia-like process which was completely reversed after reduction of lamotrigine. Associated findings included hyperre...
Gespeichert in:
| Veröffentlicht in: | OBM Neurobiology 2021-10, Vol.5 (2), p.1-1 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1 |
|---|---|
| container_issue | 2 |
| container_start_page | 1 |
| container_title | OBM Neurobiology |
| container_volume | 5 |
| creator | Brown, Joshua C Broadway, Jessica L |
| description | Lamotrigine is generally accepted as a well-tolerated medication with few cognitive side effects. Here, we report a case of a 62-year old female with a severe, rapidly progressive dementia-like process which was completely reversed after reduction of lamotrigine. Associated findings included hyperreflexia with clonus, ataxia, Wernicke-like dysphasia, global cognitive impairment, burst suppression on electroencephalogram (EEG), and bilateral parietal hypo-metabolism on fluorodeoxyglucose-Positron Emission Tomography (FDG-PET). To our knowledge, this is the first case of a severe neuropsychiatric syndrome attributed to lamotrigine at the Food and Drug administration (FDA) recommended dose and not associated with epileptic activity. |
| doi_str_mv | 10.21926/obm.neurobiol.2102091 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2805518652</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2805518652</sourcerecordid><originalsourceid>FETCH-LOGICAL-c173t-314675f690c33a690780801ab4d165dd9ab8ca68be6a436b592fdfe158af47983</originalsourceid><addsrcrecordid>eNpNkE1LAzEYhIMottT-hbJHL1vzsfk6lmpVKOhBzyHJZmtgd1OTXaH_3mBX8TTDMPO-8ACwQnCNkcTsLphu3bsxBuNDmzOIoUQXYI4pJ2VVQX75z8_AMiVvIJFcVJLjazAjPPcJRXOw2-suDNEffO_KTUrBej24uniN4RBd3n254v6Ujh86eV3ovi624dD7YcqbsbeDD_0NuGp0m9xy0gV43z28bZ_K_cvj83azLy3iZCgJqhinDZPQEqKzcAEFRNpUNWK0rqU2wmomjGO6IsxQiZu6cYgK3VRcCrIAt-e7xxg-R5cG1flkXdvq3oUxKSwgpUgwinOVnas2hpSia9Qx-k7Hk0JQ_WBUGaP6w6gmjHm4mn6MpnP13-wXGvkGbSJyYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2805518652</pqid></control><display><type>article</type><title>Lamotrigine-Associated Progressive Dysphasia and Cognitive Dysfunction</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Brown, Joshua C ; Broadway, Jessica L</creator><creatorcontrib>Brown, Joshua C ; Broadway, Jessica L ; Medical University of South Carolina, Institute of Psychiatry, 67 President Street, Charleston, SC, USA ; Warren Alpert Medical School of Brown University, 345 Blackstone Blvd, Providence, RI, USA</creatorcontrib><description>Lamotrigine is generally accepted as a well-tolerated medication with few cognitive side effects. Here, we report a case of a 62-year old female with a severe, rapidly progressive dementia-like process which was completely reversed after reduction of lamotrigine. Associated findings included hyperreflexia with clonus, ataxia, Wernicke-like dysphasia, global cognitive impairment, burst suppression on electroencephalogram (EEG), and bilateral parietal hypo-metabolism on fluorodeoxyglucose-Positron Emission Tomography (FDG-PET). To our knowledge, this is the first case of a severe neuropsychiatric syndrome attributed to lamotrigine at the Food and Drug administration (FDA) recommended dose and not associated with epileptic activity.</description><identifier>ISSN: 2573-4407</identifier><identifier>EISSN: 2573-4407</identifier><identifier>DOI: 10.21926/obm.neurobiol.2102091</identifier><identifier>PMID: 37091351</identifier><language>eng</language><publisher>United States</publisher><ispartof>OBM Neurobiology, 2021-10, Vol.5 (2), p.1-1</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37091351$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brown, Joshua C</creatorcontrib><creatorcontrib>Broadway, Jessica L</creatorcontrib><creatorcontrib>Medical University of South Carolina, Institute of Psychiatry, 67 President Street, Charleston, SC, USA</creatorcontrib><creatorcontrib>Warren Alpert Medical School of Brown University, 345 Blackstone Blvd, Providence, RI, USA</creatorcontrib><title>Lamotrigine-Associated Progressive Dysphasia and Cognitive Dysfunction</title><title>OBM Neurobiology</title><addtitle>OBM Neurobiol</addtitle><description>Lamotrigine is generally accepted as a well-tolerated medication with few cognitive side effects. Here, we report a case of a 62-year old female with a severe, rapidly progressive dementia-like process which was completely reversed after reduction of lamotrigine. Associated findings included hyperreflexia with clonus, ataxia, Wernicke-like dysphasia, global cognitive impairment, burst suppression on electroencephalogram (EEG), and bilateral parietal hypo-metabolism on fluorodeoxyglucose-Positron Emission Tomography (FDG-PET). To our knowledge, this is the first case of a severe neuropsychiatric syndrome attributed to lamotrigine at the Food and Drug administration (FDA) recommended dose and not associated with epileptic activity.</description><issn>2573-4407</issn><issn>2573-4407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpNkE1LAzEYhIMottT-hbJHL1vzsfk6lmpVKOhBzyHJZmtgd1OTXaH_3mBX8TTDMPO-8ACwQnCNkcTsLphu3bsxBuNDmzOIoUQXYI4pJ2VVQX75z8_AMiVvIJFcVJLjazAjPPcJRXOw2-suDNEffO_KTUrBej24uniN4RBd3n254v6Ujh86eV3ovi624dD7YcqbsbeDD_0NuGp0m9xy0gV43z28bZ_K_cvj83azLy3iZCgJqhinDZPQEqKzcAEFRNpUNWK0rqU2wmomjGO6IsxQiZu6cYgK3VRcCrIAt-e7xxg-R5cG1flkXdvq3oUxKSwgpUgwinOVnas2hpSia9Qx-k7Hk0JQ_WBUGaP6w6gmjHm4mn6MpnP13-wXGvkGbSJyYw</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Brown, Joshua C</creator><creator>Broadway, Jessica L</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202110</creationdate><title>Lamotrigine-Associated Progressive Dysphasia and Cognitive Dysfunction</title><author>Brown, Joshua C ; Broadway, Jessica L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c173t-314675f690c33a690780801ab4d165dd9ab8ca68be6a436b592fdfe158af47983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Brown, Joshua C</creatorcontrib><creatorcontrib>Broadway, Jessica L</creatorcontrib><creatorcontrib>Medical University of South Carolina, Institute of Psychiatry, 67 President Street, Charleston, SC, USA</creatorcontrib><creatorcontrib>Warren Alpert Medical School of Brown University, 345 Blackstone Blvd, Providence, RI, USA</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>OBM Neurobiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brown, Joshua C</au><au>Broadway, Jessica L</au><aucorp>Medical University of South Carolina, Institute of Psychiatry, 67 President Street, Charleston, SC, USA</aucorp><aucorp>Warren Alpert Medical School of Brown University, 345 Blackstone Blvd, Providence, RI, USA</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lamotrigine-Associated Progressive Dysphasia and Cognitive Dysfunction</atitle><jtitle>OBM Neurobiology</jtitle><addtitle>OBM Neurobiol</addtitle><date>2021-10</date><risdate>2021</risdate><volume>5</volume><issue>2</issue><spage>1</spage><epage>1</epage><pages>1-1</pages><issn>2573-4407</issn><eissn>2573-4407</eissn><abstract>Lamotrigine is generally accepted as a well-tolerated medication with few cognitive side effects. Here, we report a case of a 62-year old female with a severe, rapidly progressive dementia-like process which was completely reversed after reduction of lamotrigine. Associated findings included hyperreflexia with clonus, ataxia, Wernicke-like dysphasia, global cognitive impairment, burst suppression on electroencephalogram (EEG), and bilateral parietal hypo-metabolism on fluorodeoxyglucose-Positron Emission Tomography (FDG-PET). To our knowledge, this is the first case of a severe neuropsychiatric syndrome attributed to lamotrigine at the Food and Drug administration (FDA) recommended dose and not associated with epileptic activity.</abstract><cop>United States</cop><pmid>37091351</pmid><doi>10.21926/obm.neurobiol.2102091</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2573-4407 |
| ispartof | OBM Neurobiology, 2021-10, Vol.5 (2), p.1-1 |
| issn | 2573-4407 2573-4407 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2805518652 |
| source | EZB-FREE-00999 freely available EZB journals |
| title | Lamotrigine-Associated Progressive Dysphasia and Cognitive Dysfunction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T05%3A41%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lamotrigine-Associated%20Progressive%20Dysphasia%20and%20Cognitive%20Dysfunction&rft.jtitle=OBM%20Neurobiology&rft.au=Brown,%20Joshua%20C&rft.aucorp=Medical%20University%20of%20South%20Carolina,%20Institute%20of%20Psychiatry,%2067%20President%20Street,%20Charleston,%20SC,%20USA&rft.date=2021-10&rft.volume=5&rft.issue=2&rft.spage=1&rft.epage=1&rft.pages=1-1&rft.issn=2573-4407&rft.eissn=2573-4407&rft_id=info:doi/10.21926/obm.neurobiol.2102091&rft_dat=%3Cproquest_cross%3E2805518652%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2805518652&rft_id=info:pmid/37091351&rfr_iscdi=true |